Propella Therapeutics Inc.
Propella is a privately held development stage company dedicated to bringing to market best-in-class drugs that utilize an active ingredient with a known mechanism of action.
Phase-3 ready CGS-200-5 is being developed to treat osteoarthritis knee pain (OAKP). PRL-02 is being developed to treat metastatic prostate cancer.
Our current pipeline encompasses brilliant new products that offer promise for highly unmet needs.
Both CGS-200-5 and PRL-02 product candidates are covered by issued US patents that are wholly-owned by Propella.
Propella Therapeutics has developed a platform which combines lymphatic targeting with a medicinal chemistry optimization process to create therapeutics for cancer. The lead asset is PRL-02 (abiraterone decanoate) for prostate cancer.
Company Location
120 Mosaic Blvd., Suite 130-3
Pittsboro
NC
27312
Phone
County
Region
Company Details
Company type
Year founded
2020
Employment range in NC
US headquarters
North Carolina
Global headquarters
United States
Primary site activity
All company activities
Potential end market(s)
Products under development
PRL-02 (Abiraterone Decanoate) for the treatment of metastatic prostate cancer; CGS-200-5 for osteoarthritis pain